Follicle Stimulating Hormone (FSH) is a glycoprotein secreted by the anterior pituitary, necessary for mammalian reproduction. FSH helps in development and maturation of gonads at puberty, and the hormone acts by binding to FSH receptor. Endometriosis is an extra growth of endometrial tissues in the abdominal cavity. As Follicle-stimulating hormone receptor (FSHR) is present on endothelial cells of blood vessels and endometrial glands of the proliferative and secretory endometrium, FSH therapy can be very helpful in curing endometriosis.
Some of the therapies for endometriosis treatment include non-steroidal anti-inflammatory drugs (NSAIDs), progestins (medroxyprogesterone), a combination of estrogens and progestins, synthetic androgens (danazol), and gonadotropin-releasing hormone analogues with or without hormone replacement therapy and many more. Other therapies include transcutaneous electrical nerve stimulation (TENS) may be effective for the treatment of women with deep endometriosis.
For treating endometriosis, various hormonal therapies are in the market, by different companies like Teva Pharmaceuticals, Healthcare Pharmaceuticals, and Bayer. Teva has launched a drug named as Sprintec; Dienogest is marketed by Bayer HealthCare Pharmaceuticals and is considered as long term treatment for Endometriosis when administered properly.
Bayer is also in progress of developing 4 more therapies for endometriosis, out of which one relates to FSH therapy. Other companies like Abbvie (Elagolix- Phase III) and Takeda Pharmaceuticals (TAK-385; relugolix- Phase IIb) are in progress of developing appropriate hormone therapy or drug for treating Endometriosis. The field for endometriosis medicinal therapies is progressing rapidly and with the ongoing development of drugs and therapies for its treatment, the market for endometriosis treatment is on the verge of flourishing very soon in a very positive manner.